The DiaPat® technology is based on the fact that diseases are reflected by the protein composition of body fluids. World wide this knowledge is routinely used for diagnostic purposes. DiaPat® technology allows not only the analysis of a single protein biomarker, but the simultaneous analysis of hundreds of biomarkers in a single analytical step. The analytical platform was approved by U.S. Food and Drug Administration (FDA).
The test applies capillary electrophoresis coupled mass spectrometry (CE-MS). The urinary proteins are separated in an electric field by the capillary electrophoresis and are subsequently analysed in a mass spectrometer; a molecular balance that measures the molecular weight of the proteins.
The obtained data sets of more than 1 GB volume are processed and evaluated using special software solutions and are digitally compared with a disease specific DiaPat® biomarker profile (diagnostic pattern) to identify patients at high risk.